Vannini Group

The Vannini Group aims to understand how deregulation of a protein known as RNA polymerase III can cause cancer. Professor Alessandro Vannini left the ICR in July 2022, his group remains open under Professor Laurence Pearl.

Research, projects and publications in this group

Our research is aimed at mechanistically understanding the role of RNA polymerase III (and associated factors) deregulation in cancer, as well as their interplay with SMC complexes in genome structure and organisation.

The below outlines what the lab is currently focussing on.

Yeast RNA Polymerase III architecture:

We recently obtained the cryo-EM structure of yeast Pol III pre-initiation complex comprising TFIIIB, Pol III and the promoter sequence (Abascal-Palacios et al., Nature, 2018). Using state-of-the-art cryo-electron microscopy (cryo-EM) we obtained reconstructions of Pol III PIC and demonstrated the function of TFIIIB in the rearrangement of Pol III-specific subunits C34 and C37. Our study rationalised the mechanisms leading to DNA strand separation and template-strand loading into the active site and shed light into the general mechanism of gene transcription initiation. Likewise, using structural and biochemical approaches we have analysed the role of the TFIIIC transcription factor in the initial recruitment of TFIIIB to DNA promoters.

The stable association of these transcription factors to the DNA provides a platform for the further recruitment of RNA Pol III. Additionally, these assemblies are relevant for other cellular processes such the correct positioning of nucleosomes close to RNA Pol III-transcribed genes or the specific integration of Ty3 retro-transposons upstream of the transcription start site (TSS). These and other processes depend in the direct interaction of specific factors with components of TFIIIB and TFIIIC machineries.

RNA Polymerase III at type 3 promotors:

We previously demonstrated a redox control of Pol III transcription at the type 3 promoters providing a mechanistic link between Pol III deregulation and cancer (Gouge et al, 2015, Cell). We are now seeking to decipher how the promoter architecture contributes to human Pol III transcription at the type 3 promoters using structural and in vitro techniques.

TFIIIC in genome organisation:

In addition to acting as a transcription factor, TFIIIC has a potential role in genome organisation, with chromatin capture experiments localising extra TFIIIC DNA binding sites at the boundary regions of topological associating DNA domains (TADs). TFIIIC is enriched with and thought to directly interact with known genome structural protein, Condensin II at these sites. To further investigate this interaction, we are characterising human Condensin complexes using integrative approaches.

Eukaryotic transcription relies on three different RNA polymerases: RNA polymerase I (Pol) transcribes ribosomal RNA, RNA Polymerase II synthesizes messenger RNAs and RNA polymerase III produces short and non-translated RNAs, including the entire pool of tRNAs, which are essential for cell growth.

For a long time, it was assumed that only Pol II was regulated whereas Pol I and Pol III, being devoted to house-keeping genes, did not require such control. However, growing evidence show that RNA Polymerase III transcription is tightly regulated. Deregulation of its recruitment has been linked to neurodegenerative diseases and cancer.

RNA Pol III is recruited at only 3 types of promoters. While the type 1 and 2 are conserved from yeast to human, the type 3 promoters are found solely in higher eukaryotes. At the type 1 and 2, TFIIIC binds the promoter sequence to recruit TFIIIB that places the polymerase at the transcriptional start site. In humans, several tumour suppressors proteins and oncogenes interact directly with the transcription factor TFIIIB and, as a consequence, modulate RNA polymerase III occupancy at target genes. During carcinogenesis, this layer of regulation is lost, resulting in an augmented RNA polymerase III transcriptional output. Our research is aimed at mechanistically understanding the role of RNA polymerase III deregulation in cancer.

It is becoming increasingly clear that Pol III (and its associated factors) play a paramount role into genome structure and organisation. These extratranscriptional roles are effected through interactions with transposon machineries, SMC complexes and specific chromatin remodellers; we are aiming to obtain a detailed mechanistic understanding of these fundamental processes.

Professor Laurence Pearl

Head of Division:

Vannini Group, Macromolecular Structural Biology Laurence Pearl (Profile)

Professor Pearl seeks to understand the structural basis for assembly, specificity and regulation of the multi-protein complexes involved in the recognition, repair and signalling of DNA damage, and in the chaperone-mediated stabilisation and activation of cellular signalling pathways. These basic studies provide the means for discovery and development of novel small-molecule inhibitors with application as drugs for the treatment of cancer and other diseases.

Researchers in this group

.

Email: [email protected]

Location: Chelsea

Professor Laurence Pearl's group have written 215 publications

Most recent new publication 8/2024

See all their publications

News and discoveries from Vannini Group

01/07/20

DNA helix 945x532

Image: Shadow of a DNA double helix on coloured DNA sequencing output. Credit: Peter Artymiuk, Wellcome Collection, CC BY 4.0

Scientists at The Institute of Cancer Research have uncovered new information about vital structures inside cells which are responsible for organising our DNA.

Using state-of-the-art imaging techniques, the team were able to look at two critical structures responsible for condensing DNA into chromosomes, called condensin I and condensin II.

The findings could have major implications for understanding how cancer develops, since these structures often become deregulated in cancer cells, leading to harmful mutations in the DNA.

Building a structural model

In a new study, carried out by scientists at The Institute of Cancer Research in conjunction with a team at Columbia University in the USA and published in the journal Molecular Cell, the scientists were able to look at individual condensin molecules using electron microscopy and examine the activity of condensin molecules using a technique called single-molecule imaging.

This involves taking some of the innards of a cell and placing them under a microscope to examine what they are doing in extraordinary detail.

Electron microscopy can be used to look at structures as small as DNA, and using this method the scientists could examine individual condensin molecules.

By putting lots of images of condensin together, they could build a structural model of condensin, which showed it has passages through its structure that could hold DNA.

By labelling condensin molecules with a kind of fluorescent luggage tag, the researchers could also follow the activity of the molecules and see condensin making loops in DNA.

Condensing DNA

Stretching out all of the DNA in just one human cell, it would measure around three meters end to end. Since most human cells measure just a fraction of the width of a human hair, the cell must condense all of this DNA down to fit it into the cell, much like packing a very long rope into a very small bag.

The role of condensin inside a cell is to do this in an organised way, avoiding knots. Many condensin molecules work to make many loops of DNA, all coiled around special proteins called histones.

Sections of DNA coiled around histones form structures which look like small beads along the length of DNA, giving a structure that looks something like a set of fairy lights used to decorate a Christmas tree.

These structures of DNA coiled around histones are called nucleosomes.

We are building a new state-of-the-art drug discovery centre to develop a new generation of drugs that will make the difference to the lives of millions of people with cancer. Find out more about the challenge of cancer drug resistance and help fund research to help finish cancer.

Find out more

Shedding light on how condensin works

The new study, funded by the Wellcome Trust, Cancer Research UK and the ICR, was able to shed light on the ability of human condensin I and II to ‘jump’ over these nucleosomes.

It was not previously known if condensins could continue to condense DNA effectively with nucleosomes in the way, but results in this work showed that the structures are unphased by the presence of nucleosomes.

Co-leading author Dr Erin Cutts, Post-Doctoral Training Fellow in Structural Biology at the ICR, said:

“In this work we could directly see human condensin I and II making DNA loops and see how individual molecules were structured, allowing us new insights into how condensin works. It was hugely exciting collecting this data!”

Study co-leader Professor Alessandro Vannini, Team Leader in Structural Biology at the ICR, said:

“These two complexes are often altered in many different types of cancer, so understanding the structure and function could help with future work to develop new treatments.”

This work was produced by a team of researchers including ICR researchers Professor Alessandro Vannini, Dr Erin Cutts, Dr Thangavelu Kaliyappan, Dr Edward Morris and Dr Fabienne Beuron.